Gerresheimer AG
XETRA:GXI
Gerresheimer AG
XETRA:GXI
Price:
94.6 EUR
-3.86%
Market Closed
Updated:
May 21, 2024
Gerresheimer AG
Cost of Revenue
|
Gerresheimer AG
Cost of Revenue Peer Comparison
Comparables:
E
EVT
S
1SXP
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gerresheimer AG
XETRA:GXI
|
Cost of Revenue
-€1.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
E
|
Evotec SE
XETRA:EVT
|
Cost of Revenue
-€606.4m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-27%
|
|
S
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Cost of Revenue
-€582.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Gerresheimer AG's Cost of Revenue?
Cost of Revenue
-1.4B
EUR
-1.4B
EUR
Based on the financial report for Feb 29, 2024, Gerresheimer AG's Cost of Revenue amounts to -1.4B EUR.
What is Gerresheimer AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-5%
-5%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Gerresheimer AG have been -13% over the past three years , -7% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
